A meta-analysis of cardiovascular outcome trials found that GLP-1 receptor agonists significantly reduced major adverse cardiovascular events, cardiovascular death, and all-cause mortality in type 2 diabetes, with effect sizes amplified in older individuals and those with higher baseline BMI. These findings support preferential use of GLP-1RAs in heavier and older patients at elevated CV risk when personalizing therapy choices. To read more Click Here ##Reference## Kalayci A, Januzzi JL, Mitsunami M, Tanboga IH, Karabay CY, Gibson CM. Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis.
Eur Heart J Cardiovasc Pharmacother. 2025;11(6):552-561.## In your experience, which patient profile most strongly pushes you toward a GLP-1RA for CV risk reduction Older patient with high BMI and established ASCVD Younger lean…
